Clinical Study to Assess Efficacy and Safety of MDA-TIL (Autologous Expanded Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types
MD Anderson Study Status
Autologous Tumor Infiltrating Lymphocytes MDA-TIL, Cyclophosphamide, Fludarabine, Interleukin-2
This phase II trial studies how well autologous tumor infiltrating lymphocytes MDA-TIL works in treating patients with ovarian cancer, colorectal cancer, or pancreatic ductal adenocarcinoma that has come back (recurrent) or does not respond to treatment (refractory). Autologous tumor infiltrating lymphocytes MDA-TIL, made by collecting and growing specialized white blood cells (called T-cells) from a patient's tumor, may help to stimulate the immune system in different ways to stop tumor cells from growing.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Malignant Solid Neoplasm, Metastatic Colorectal Adenocarcinoma, Metastatic Ovarian Carcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Platinum-Resistant Ovarian Carcinoma, Recurrent High Grade Ovarian Serous Adenocarcinoma, Recurrent Ovarian Carcinosarcoma, Refractory Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Gynecologic Oncology & Reproductive Medicine
For general questions about clinical trials:
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.